Comparative Pharmacology
Head-to-head clinical analysis: CHENODIOL versus URSODIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHENODIOL versus URSODIOL.
CHENODIOL vs URSODIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chenodiol is a bile acid that reduces cholesterol saturation in bile by suppressing hepatic synthesis of cholesterol and inhibiting intestinal absorption of cholesterol. It also expands the bile acid pool and decreases biliary cholesterol secretion, promoting dissolution of cholesterol gallstones.
Ursodiol is a hydrophilic bile acid that reduces the concentration of hydrophobic bile acids, thereby decreasing cholesterol secretion into bile and promoting dissolution of cholesterol gallstones. It also exerts cytoprotective effects on hepatocytes by stabilizing cell membranes and reducing apoptosis in cholestatic liver diseases.
13-15 mg/kg/day orally in 2-4 divided doses, typically starting at 250 mg twice daily, then increasing by 250 mg/day every 1-2 weeks to full dose.
13-15 mg/kg/day orally divided into 2-4 doses for cholesterol gallstones; 13-15 mg/kg/day orally divided into 2-4 doses for primary biliary cholangitis.
None Documented
None Documented
Terminal elimination half-life: 3-5 days. Clinical context: Prolonged due to enterohepatic recycling; steady-state achieved in 3-4 weeks.
Terminal elimination half-life: 3.5–5.8 days for endogenous bile acids; for exogenous ursodiol, half-life is approximately 4–6 days, reflecting slow turnover of bile acid pool.
Primarily biliary (renal excretion minimal; <1% unchanged in urine). Fecal excretion as metabolites.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<1% unchanged in urine).
Category C
Category A/B
Gallstone Dissolution Agent
Gallstone Dissolution Agent